Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report)'s share price dropped 5.5% during trading on Tuesday . The company traded as low as $4.65 and last traded at $4.77. Approximately 1,594,521 shares traded hands during trading, a decline of 18% from the average daily volume of 1,953,979 shares. The stock had previously closed at $5.05.
Wall Street Analyst Weigh In
Several analysts recently weighed in on XERS shares. Oppenheimer lifted their price target on Xeris Biopharma from $6.00 to $7.00 and gave the stock an "outperform" rating in a report on Friday, May 9th. HC Wainwright reaffirmed a "buy" rating and issued a $8.00 price objective (up from $6.60) on shares of Xeris Biopharma in a report on Friday, March 7th. Wall Street Zen downgraded shares of Xeris Biopharma from a "buy" rating to a "hold" rating in a report on Thursday, May 22nd. Leerink Partners raised their price objective on Xeris Biopharma from $5.00 to $6.00 and gave the company an "outperform" rating in a research note on Friday, March 7th. Finally, Craig Hallum boosted their price objective on Xeris Biopharma from $5.00 to $6.50 and gave the stock a "buy" rating in a research report on Friday, March 7th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $6.25.
Read Our Latest Stock Analysis on XERS
Xeris Biopharma Stock Performance
The company has a market cap of $692.79 million, a P/E ratio of -9.84 and a beta of 1.10. The firm's 50 day moving average price is $4.59 and its two-hundred day moving average price is $4.05.
Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.01. The firm had revenue of $57.80 million during the quarter, compared to analyst estimates of $57.61 million. As a group, analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current fiscal year.
Insider Activity at Xeris Biopharma
In related news, insider Beth Hecht sold 40,000 shares of the firm's stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $5.43, for a total value of $217,200.00. Following the transaction, the insider now owns 1,353,510 shares of the company's stock, valued at approximately $7,349,559.30. This trade represents a 2.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.47% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the stock. Nuveen LLC purchased a new stake in Xeris Biopharma in the 1st quarter valued at $12,240,000. Parkman Healthcare Partners LLC grew its stake in shares of Xeris Biopharma by 207.8% in the 1st quarter. Parkman Healthcare Partners LLC now owns 1,780,454 shares of the company's stock worth $9,775,000 after acquiring an additional 1,201,943 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Xeris Biopharma by 75.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company's stock valued at $15,317,000 after purchasing an additional 1,199,435 shares during the last quarter. Invesco Ltd. lifted its position in shares of Xeris Biopharma by 1,387.8% during the first quarter. Invesco Ltd. now owns 1,026,838 shares of the company's stock valued at $5,637,000 after purchasing an additional 957,822 shares in the last quarter. Finally, Driehaus Capital Management LLC boosted its holdings in Xeris Biopharma by 137.6% during the first quarter. Driehaus Capital Management LLC now owns 1,411,540 shares of the company's stock worth $7,749,000 after purchasing an additional 817,525 shares during the last quarter. Institutional investors own 42.75% of the company's stock.
Xeris Biopharma Company Profile
(
Get Free Report)
Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
See Also
Before you consider Xeris Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xeris Biopharma wasn't on the list.
While Xeris Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
